Alcon Loses Staar Surgical Merger as FDA Opens 8 Million Patient Lens Market
Alcon’s planned merger with Staar Surgical was terminated after it failed to secure stockholder approval, ending Alcon’s direct access to Staar’s EVO/EVO+ ICL technology. The FDA has expanded the EVO ICL age indication to 21–60 years, opening an 8 million patient market Alcon now must pursue independently.
1. Merger Termination
Alcon and Staar Surgical’s proposed merger agreement was terminated after Staar Surgical stockholders did not vote to approve the transaction. This outcome removes Alcon’s planned access to Staar’s established EVO/EVO+ Visian ICL platform, forcing Alcon to reassess its vision correction strategy.
2. Expanded FDA Approval
The FDA has broadened the age range for the EVO/EVO+ ICL from 21–45 to 21–60 years, potentially adding nearly 8 million U.S. refractive patients to the lens-based vision correction market. Clinical data covering three years and 629 eyes showed a safety index of 1.25, zero pupillary block cases and a cataract incidence of just 0.16%.
3. Strategic Implications for Alcon
With the merger off, Alcon loses immediate exposure to a leading lens-based solution in a market shifting away from LASIK, where over half of consumers now favor implantable lenses. Alcon must explore internal development or new partnerships to capture the newly accessible patient base.